Rare Disease vs Gastroenterology — Deal Terms Comparison

Rare Disease Median Upfront

$285M

Total: $1.6B

Gastroenterology Median Upfront

$529M

Total: $2.7B

Rare Disease Royalties

7.8%-15.6%

Tiered to 19.6%

Gastroenterology Royalties

7.7%-14.2%

Tiered to 18.2%

Model Your Deal

Market Analysis

Rare Disease and Gastroenterology represent distinct licensing landscapes with different risk-reward dynamics. Phase 2 rare disease deals carry a median total deal value of $1.6B with $285M upfront, compared to $2.7B total value and $529M upfront for gastroenterology. The differences reflect divergent clinical development timelines, regulatory pathways, and addressable market sizes.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How do rare disease and gastroenterology deal terms compare?

Rare Disease Phase 2 deals average $1.6B total value ($285M upfront), while Gastroenterology deals average $2.7B ($529M upfront). The differences are driven by addressable market size, clinical development complexity, and regulatory pathway characteristics.

Which therapeutic area commands higher royalty rates: Rare Disease or Gastroenterology?

Rare Disease base royalties range from 7.8% to 15.6%, while Gastroenterology royalties range from 7.7% to 14.2%. Royalty rates reflect pricing power, competitive dynamics, and patent protection characteristics specific to each therapeutic area.

What drives the deal value differences between rare disease and gastroenterology?

Key factors include addressable patient population size, clinical trial costs and timelines, regulatory pathway complexity, pricing and reimbursement dynamics, and competitive landscape density. Rare Disease and Gastroenterology each have unique value drivers that shape deal economics.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Rare Disease vs Gastroenterology — Deal Terms Comparison

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Rare Disease Deal Overview

Gastroenterology Deal Overview

Phase 2 Deal Benchmarks

Ready to Calculate Your Deal Terms?